MyelinWatch EL
← Pipeline
Human clinical dataCompletedNegative

Phase 2 • completed

PIPE-307 / VISTA

M1R antagonist

Practical availability: Research record — not presented as established care

Compound / intervention
M1R antagonist
Mechanism
M1 muscarinic-receptor antagonism
Development stage
Phase 2 • completed
Status
Efficacy endpoints not met
Evidence level
Human Phase 2 • efficacy endpoints not met
Next substantive checkpoint

Further development in MS remains uncertain

Company filingOpen source ↗Last checked: 16 Sep 2026

Related substantive developments

Human clinical dataCompletedNegative

Phase 2

PIPE-307: Phase 2 VISTA missed its efficacy endpoints

In relapsing-remitting MS, VISTA reported acceptable safety and tolerability, but PIPE-307 did not meet its prespecified primary or secondary efficacy endpoints.

Practical availability: Research record — not presented as established care

What this means clinically

One of the most discussed remyelination-specific compounds did not demonstrate clinical efficacy in Phase 2; further MS development remains uncertain.

Source quality: High for topline status • official SEC filing, not a peer-reviewed full paper

Company filingContineum / SEC filing ↗